Vaccine Contract Manufacturing
Vaccine Contract Manufacturing Market by Service Type (Analytical and Testing Services, Bulk Production, Fill and Finish Operations), Vaccine Type (Inactivated Vaccines, Live Attenuated Vaccines, Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines), Technology Platform, End User, Age Group - Global Forecast 2025-2030
SKU
MRR-430D42AA0DC4
Region
Global
Publication Date
January 2025
Delivery
Immediate
2024
USD 5.51 billion
2025
USD 6.04 billion
2030
USD 9.40 billion
CAGR
9.29%
360iResearch Analyst Ketan Rohom
Download a Free PDF
Get a sneak peek into the valuable insights and in-depth analysis featured in our comprehensive vaccine contract manufacturing market report. Download now to stay ahead in the industry! Need more tailored information? Ketan is here to help you find exactly what you need.

The Vaccine Contract Manufacturing Market size was estimated at USD 5.51 billion in 2024 and expected to reach USD 6.04 billion in 2025, at a CAGR 9.29% to reach USD 9.40 billion by 2030.

Vaccine Contract Manufacturing Market
To learn more about this report, request a free PDF copy

The vaccine contract manufacturing market involves outsourcing vaccine production to third-party manufacturers, allowing pharmaceutical companies to leverage specialized expertise, infrastructure, and capacity without the need for large capital investments. This is increasingly necessary due to the growing demand for vaccines driven by factors such as the prevalence of infectious diseases, increasing vaccine coverage, and the need for rapid response capabilities, as seen during the COVID-19 pandemic. Applications span across a variety of end-use sectors including public health institutions, private vaccine producers, and research laboratories. Market growth is fueled by advancements in biotechnology, increasing strategic collaborations between biotechnology firms and CMOs (Contract Manufacturing Organizations), and scaling up of production capacities to meet global increases in demand. Key opportunities lie in the implementation of advanced technologies such as single-use bioreactors and continuous manufacturing processes, which enhance efficiency and reduce production timelines. Additionally, the rising trend towards personalized medicine and mRNA vaccines presents avenues for innovation and expansion. However, the market faces challenges such as stringent regulatory environments, intellectual property concerns, and supply chain disruptions which may hinder growth. Moreover, competition among CMOs can negatively impact pricing strategies. To address these challenges, companies are encouraged to invest in comprehensive regulatory compliance strategies and explore public-private partnerships to mitigate risks and costs. As a part of recommendations, tapping into emerging markets where vaccine demand is high but production capabilities are limited can be lucrative. The industry also holds potential for research in developing flexible manufacturing solutions capable of swiftly adapting to new vaccines and changing demands. Ultimately, the vaccine contract manufacturing market is dynamic, marked by fierce competition and significant growth opportunities, necessitating continuous innovation and strategic agility for sustainable business advancement.

Ask ResearchAI anything

World's First Innovative Al for Market Research

Ask your question about the Vaccine Contract Manufacturing market, and ResearchAI will deliver precise answers.
How ResearchAI Enhances the Value of Your Research
ResearchAI-as-a-Service
Gain reliable, real-time access to a responsible AI platform tailored to meet all your research requirements.
24/7/365 Accessibility
Receive quick answers anytime, anywhere, so you’re always informed.
Maximize Research Value
Gain credits to improve your findings, complemented by comprehensive post-sales support.
Multi Language Support
Use the platform in your preferred language for a more comfortable experience.
Stay Competitive
Use AI insights to boost decision-making and join the research revolution at no extra cost.
Time and Effort Savings
Simplify your research process by reducing the waiting time for analyst interactions in traditional methods.

Market Dynamics

The market dynamics represent an ever-changing landscape of the Vaccine Contract Manufacturing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

  • Market Drivers
    • How increasing global health awareness and disease prevention drive vaccine contract manufacturing
    • The role of advanced technology in fueling innovation within vaccine contract manufacturing
    • Exploring the significant factors fostering growth in the vaccine contract manufacturing sector
  • Market Restraints
    • Key market constraints hindering vaccine contract manufacturing growth and scalability
    • Navigating regulatory and demand constraints in the vaccine contract manufacturing sector
    • Dissecting financial and logistical limitations in contract manufacturing of vaccines
  • Market Opportunities
    • Developing cost-efficient, scalable technologies for rapid adaptation to emerging infectious diseases
    • Expanding cold chain logistics solutions to enhance shelf-life and distribution of vaccines worldwide
    • Targeting regions with underdeveloped biologics manufacturing capacities to establish local footprints
  • Market Challenges
    • Overcoming the pricing pressures and cost constraints affecting the profitability of manufacturing contracts
    • Addressing the global supply chain disruptions and logistical challenges in sourcing raw materials for vaccines
    • Ensuring stringent quality control and assurance standards in every stage of vaccine manufacturing

Market Segmentation Analysis

  • Type: Growing adoption of attenuated vaccines to enhance immune systems

    An attenuated vaccine uses a live version of the virus or bacteria that has been weakened, which cannot cause disease in people with healthy immune systems. This type of vaccine elicits a strong immune response and often requires fewer doses for long-term immunity. DNA vaccines employ a piece of genetic material from a pathogen to elicit an immune response. They direct the body's cells to produce an antigen that is native to the pathogen, prompting a specific immune response. DNA vaccines are still a relatively new technology and offer potential advantages in speed of development and stability, making them an interesting avenue for contract manufacturing. Inactivated vaccines contain viruses or bacteria that have been killed through physical or chemical processes. These vaccines do not pose a risk of causing the disease itself and are stable, making them suitable for a broad range of environments. Inactivated vaccines generally require adjuvants to enhance the immune response and may require multiple doses. Subunit vaccines include only the essential antigens of a virus or bacteria—rather than the whole pathogen. This approach minimizes the risk of side effects and is particularly useful when the pathogen cannot be cultivated in vitro or when the whole organism is unnecessary for immunization. Toxoid vaccines contain inactivated toxic compounds produced by bacteria that cause illness rather than the bacteria itself. These vaccines train the immune system to fight off the natural toxin, offering protection if the immunized individual ever encounters the actual pathogen. They are particularly useful for bacteria, such as Clostridium tetani, the cause of tetanus, where toxin production is the main cause of disease.

  • Function: Increasing usage of downstream processing formulations that involve the purification and formulation of the bioproducts

    Downstream processing refers to the phase of vaccine manufacturing where the bulk product is refined and purified to meet regulatory standards and quality requirements. Key steps in downstream processing include the separation of cells and virus particles, removal of contaminants, and concentration and formulation of the vaccine. The need for downstream processing arises from the necessity to ensure that vaccines are safe, pure, and effective before they can be administered to the public. Upstream processing in vaccine manufacturing includes all steps necessary for the growth and initial harvest of the vaccine-producing biological system. This generally involves the culturing of cells or microorganisms that generate the vaccine antigen. The preference for cutting-edge upstream processing technologies stems from the fundamental need for consistent, scalable, and high-yield vaccine production.

Porter’s Five Forces Analysis

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Vaccine Contract Manufacturing Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

PESTLE Analysis

The PESTLE analysis offers a comprehensive tool for understanding and analyzing the external macro-environmental factors that impact businesses within the Vaccine Contract Manufacturing Market. This framework examines Political, Economic, Social, Technological, Legal, and Environmental factors, providing companies with insights into how these elements influence their operations and strategic decisions. By using PESTLE analysis, businesses can identify potential opportunities and threats in the market, adapt to changes in the external environment, and make informed decisions that align with current and future conditions. This analysis helps companies anticipate shifts in regulation, consumer behavior, technology, and economic conditions, allowing them to better navigate risks and capitalize on emerging trends.

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Vaccine Contract Manufacturing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Vaccine Contract Manufacturing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Recent Developments

  • Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)

    Vaxcyte, Inc. has reinforced its collaboration with Lonza Group AG, a contract development and manufacturing organization, to ensure the global launch preparedness of its line of pneumococcal conjugate vaccines (PCVs), namely VAX-24 and VAX-31, intended to protect both adult and pediatric demographics. In a significant deal, Vaxcyte will rely on Lonza's considerable manufacturing expertise to expedite the clinical progression of its vaccine candidates, beginning with VAX-24 in the US adult market. To meet the expected long-term worldwide demand, Lonza is dedicated to the establishment of a custom manufacturing suite at their state-of-the-art Ibex Dedicate Biopark in Visp, Switzerland, with the completion of its construction design and equipment installation slated for 2024. [Published On: October 16, 2023]

  • Oxford Acquires ABL Europe From Institut Mérieux For EUR 15 Mn

    Oxford Biomedica plc, a vaccine contract development and manufacturing organization (CDMO), has purchased ABL Europe SAS from TSGH SAS, part of the Institut Mérieux Group, for a total consideration of EUR 15 million. The deal encompasses EUR 10 million of liquid assets infused into ABL Europe by Institut Mérieux before completion. The integration of ABL Europe into Oxford Biomedica's operations is expected to catapult the latter into the vanguard of global CDMOs within the cell and gene therapy field, enhancing its service offering and increasing its production capabilities, especially in process and analytical development, as well as early-stage manufacturing. [Published On: April 12, 2023]

  • Pfizer Inks USD 183M Contract Manufacturing Deal With Samsung Biologics

    Samsung Biologics has confirmed its contract with Pfizer Inc. to manufacture COVID-19 vaccines for Moderna in a regulatory announcement, valued at 241 billion WON (USD 183 million), valid through 2029. As disclosed by the company, Samsung is directing substantial investment into the development of antibody-drug conjugates (ADCs), with manufacturing capabilities anticipated to come online within the year at their Incheon facility, fostering growth and diversification in their service offerings. [Published On: March 02, 2023]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Vaccine Contract Manufacturing Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Vaccine Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc, Ajinomoto Bio-Pharma Services by Ajinomoto Co., Inc., Aton (Shanghai) Biotech Co., Ltd., Avid Bioservices, Inc., Catalent, Inc., Charles River Laboratories International, Inc., CSL Limited, Curia Global, Inc., Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Emergent BioSolutions Inc., FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation, Gedeon Richter PLC, GlaxoSmithKline PLC, ICON PLC, IDT Biologika GmbH, KBI Biopharma, Inc. by JSR Corporation, Klocke Pharma-Service GmbH, Lonza Group Ltd., Merck KGaA, Moderna, Inc., Pfizer Inc., Pharmaceutical Product Development by Thermo Fisher Scientific Inc., Recipharm AB, Serum Institute of India, and Vetter Pharma-Fertigung GmbH & Co. KG.

Market Segmentation & Coverage

This research report categorizes the Vaccine Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Service Type
    • Analytical and Testing Services
      • Quality Control Testing
      • Stability Studies
    • Bulk Production
      • Antigen Manufacturing
      • Peptide Synthesis
    • Fill and Finish Operations
      • Aseptic Filling
      • Vial Labeling and Packaging
    • Regulatory Support Services
      • Compliance Management
      • Submission Preparation
  • Vaccine Type
    • Inactivated Vaccines
      • Fractional Vaccines
      • Whole Cell
    • Live Attenuated Vaccines
      • Bacterial Vector-Based Vaccines
      • Viral Vector-Based Vaccines
    • Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines
      • Polysaccharide Antigens
      • Surface Protein Subunits
    • Toxoid Vaccines
      • Diphtheria
      • Tetanus
  • Technology Platform
    • mRNA Technology
      • Cold Chain Technology Enhancements
      • Lipid Nanoparticle Delivery
    • Nanoparticle Technology
      • Biopolymer Nanoparticles
      • Metal Nanoparticles
    • Protein-Based Technology
      • Cell Line Development
      • Protein Purification Techniques
    • Recombinant DNA Technology
      • Expression Systems
      • Vector Development
  • End User
    • Academic and Research Institutes
      • Collaborative Research Projects
      • Government-Funded Research
    • Government and Other Health Institutions
      • Global Health Partnerships
      • National Immunization Programs
    • Pharmaceutical and Biotechnology Companies
      • Contract Manufacturing Organizations
      • Vaccine R&D Divisions
    • Vaccination Service Providers
      • Hospitals
      • Primary Healthcare Centers
  • Age Group
    • Adult
      • Middle-Aged Adults
      • Young Adults
    • Geriatric
      • Elderly with Chronic Conditions
      • Seniors
    • Pediatric
      • Children and Adolescents
      • Infants
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

This research report offers invaluable insights into various crucial aspects of the Vaccine Contract Manufacturing Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?
Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Vaccine Contract Manufacturing Market, by Service Type
  7. Vaccine Contract Manufacturing Market, by Vaccine Type
  8. Vaccine Contract Manufacturing Market, by Technology Platform
  9. Vaccine Contract Manufacturing Market, by End User
  10. Vaccine Contract Manufacturing Market, by Age Group
  11. Americas Vaccine Contract Manufacturing Market
  12. Asia-Pacific Vaccine Contract Manufacturing Market
  13. Europe, Middle East & Africa Vaccine Contract Manufacturing Market
  14. Competitive Landscape
Frequently Asked Questions
  1. How big is the Vaccine Contract Manufacturing Market?
    Ans. The Global Vaccine Contract Manufacturing Market size was estimated at USD 5.51 billion in 2024 and expected to reach USD 6.04 billion in 2025.
  2. What is the Vaccine Contract Manufacturing Market growth?
    Ans. The Global Vaccine Contract Manufacturing Market to grow USD 9.40 billion by 2030, at a CAGR of 9.29%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.